CTOs on the Move

Alpha Medical

www.helloalpha.com

 
Your doctor’s office is now online. From primary care to mental health, we’ve got you covered.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Goldsmith Medical Co

Goldsmith Medical Co is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Schwartz Group

The Schwartz Group is a Buffalo, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

United Claim Solutions

United Claim Solutions was started by Joshua Carder in 2004. Joshua had been in the cost containment industry for a number of years, and through that experience realized there were efficiencies and solutions that could be introduced to lower medical and administrative costs for self-insured employers, labor organizations, payers and insurers. The mission of United Claim Solutions is to be a leader and innovator of products and services for healthcare payers. We will provide superior Service, Savings and Solutions to our customers while never compromising the quality of care delivered to covered individuals.

MSP Corporation

MSP Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.